Navigation Links
Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
Date:7/1/2008

REHOVOT, Israel, July 1 /PRNewswire-FirstCall/ -- Applisonix LTD (TASE: APLS), a developer of innovative ultrasound based solutions for the aesthetic market, announced today that the test conducted using its hair removal prototype achieved, following an initial treatment, average hair reduction of 38%, which positions its efficacy within the top professional long-term hair removal solutions.

Applisonix' co-CEOs, Mr. Alon Goren and Mr. Uri Amir, stated that the test results indicate that the technology developed by Applisonix can be safely and effectively implemented for men and women. Mr. Goren estimates that compared to commercially available long-term hair removal solutions, Applisonix' solutions are planned to be safer, less painful, more affordable, and applicable to all hair and skin tones, Mr. Amir added that the company intends to launch its first device, Selectif(TM), in the first quarter of 2009, as planned.

Applisonix conducted tests on men and women for a period of several months. The test results were examined by Prof. Kassuto (Milan, Italy), an external, independent, internationally recognized expert. Prof. Kassuto verified and evaluated the findings and concluded that the new technology's efficacy is similar to the efficacy of the top commercial light based systems, and without any side effects, and regardless of hair and skin color.

In addition, it appears from Prof. Kassuto's review, that following the initial treatment using the prototype and Applisonix' technology (IMPRESA(TM)), there was an average 38% hair reduction, compared to the controlled area, which was not treated. The treatment was given to 36 people, men and women, with different hair colors and skin tones, and the results were statistically significant.

These results reflect the new technology's capability of competing with expensive professional light-based systems. From studies published in this field, it seems that with most light based systems, one treatment can reduce the hair count by 10%-40%, thus the results position Applisonix' technology within the highest level of hair removal technologies.

Prof. Yitzhak Peterburg, Applisonix' chairman, stated that this breakthrough paves the road for Applisonix to join the leading aesthetic companies in the world in the hair removal market. "Applisonix", added Peterburg "presents a combination of an innovative, exciting technology, a huge potential market, and impressive execution capabilities."

For further information please contact:

Israel: USA:

Alon Goren - Co-CEO Yossi Aloni - VP Marketing and Business

Uri Amir - Co-CEO Development

+972(8)936-3604 +1-858-427-5279


'/>"/>
SOURCE Applisonix Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Announces Board Changes
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
7. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
10. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
11. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... India , February 8, 2016 ... a new market research report "Ablation Technologies Market by ... (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - ... studies the global market over the forecast period of ... $4.44 Billion by 2020, at CAGR of 10.5% from ...
(Date:2/8/2016)... Kan. , Feb. 8, 2016 /PRNewswire/ ... organization that formerly specialized in the development ... recently announced that it has divided its ... Capital. While Nueterra Capital will continue the ... services, NueHealth will operate a national system ...
(Date:2/8/2016)... , Feb. 8, 2016  A research team ... scientists has discovered details of how the abnormal breakage ... a particularly aggressive form of acute lymphoblastic leukemia (ALL). ... which genetic mutations trigger overproduction of immature cells, called ... The discoveries of the malfunction underlying the type called ...
Breaking Medicine Technology:
(Date:2/8/2016)... Park, KS (PRWEB) , ... February 08, 2016 , ... ... a leader in Mole removal products. , Moles are derived from a cluster of ... appear in all the wrong places and create a lifetime of embarrassment. Historically, ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/8/2016)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase patient awareness of the lack of ... to inform dentists and patients about the possible lack of skills and knowledge ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/7/2016)... AZ (PRWEB) , ... February 07, 2016 , ... ... Neck and Facial Plastics, has added Kybella® to his medical and surgical expertise. ... a newly approved FDA injectable medication used as a non-surgical alternative for reduction ...
Breaking Medicine News(10 mins):